PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
LA JOLLA, Calif. , Dec. 19, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has initiated the first-in-human Phase I study of RGLS4326 and
View HTML
PDF Version
Toggle Summary Regulus Reports Third Quarter 2017 Financial Results and Recent Events
Conference Call Today at 5:00 p.m. ET LA JOLLA, Calif. , Nov. 7, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today summarized recent events and reported financial
View HTML
Toggle Summary Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017
Conference Call and Webcast to Follow LA JOLLA, Calif. , Oct. 31, 2017 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide third quarter 2017
View HTML
Toggle Summary Regulus to Present at the 2017 Wells Fargo Healthcare Conference
LA JOLLA, Calif. , Aug. 30, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present
View HTML
Toggle Summary Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference
LA JOLLA, Calif. , Aug. 8, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present
View HTML
Toggle Summary Regulus Reports Second Quarter 2017 Financial Results and Recent Events
Completed Public Offering Raising $46 Million in Gross ProceedsConference Call Today at 5:00 p.m. ET
View HTML
Toggle Summary Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
LA JOLLA, Calif. , July 25, 2017 /PRNewswire/ -- Regulus Therapeutics Inc.  (NASDAQ: RGLS) , a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the completion of its previously announced underwritten public offering of 50,600,000 shares of its common
View HTML
Toggle Summary Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017
Conference Call and Webcast to Follow
View HTML
Toggle Summary Regulus Announces Pricing of Public Offering of Common Stock
LA JOLLA, Calif. , July 19, 2017 /PRNewswire/ --   Regulus Therapeutics Inc.  (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at the price to the
View HTML
Toggle Summary Regulus Announces Commencement of Public Offering of Common Stock
LA JOLLA, Calif. , July 19, 2017 /PRNewswire/ --  Regulus Therapeutics Inc.  (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and
View HTML
Displaying 11 - 20 of 227 results
MENU